ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFrais de vente, généraux et administratifs101.51 M99.32 M107.56 M130.73 M116.21 M110.22 M464.71 MRecherche et développement35.33 M36.31 M45.49 M48.02 M47.48 M39.38 M180.37 MRésultat d'exploitation113.87 M102.07 M87.97 M43.62 M77.18 M81.33 M290.09 MTotal des produits hors exploitation8.9 M14.05 M6.55 M2.29 M7.43 M66.24 M82.51 MCharges d'intérêts, nettes des intérêts capitalisés5.04 M4.8 M4.92 M4.95 M5.08 M4.86 M19.81 MRésultat hors exploitation, hors charges d'intérêts-5.59 M-4.88 M-5.26 M-5.22 M-5.39 M55.67 M39.79 MRevenus/dépenses exceptionnels9.45 M14.13 M6.89 M2.56 M7.75 M5.71 M22.91 MRésultat avant impôts-783 K96.53 M104.52 M42.38 M70.36 M156.41 M373.67 MPart des actionnaires dans le résultat———————Impôts11.01 M23.58 M25.76 M14.61 M16.28 M37.99 M94.64 MIntérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts-5.02 M-822 K-2.44 M-2.26 M348 K2.32 M-2.04 MRésultat net avant activités abandonnées-11.79 M72.94 M78.75 M27.77 M54.09 M118.42 M279.03 MActivités abandonnées———————Résultat net-11.79 M72.94 M78.75 M27.77 M54.09 M118.42 M279.03 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires-11.79 M72.94 M78.75 M27.77 M54.09 M118.42 M279.03 MBénéfice par action de base (BPA de base)-0.171.061.150.410.841.834.23Bénéfice par action dilué (BPA dilué)-0.181.021.120.410.861.84.19Nombre moyen d'actions de base en circulation69.2 M68.67 M68.52 M67.23 M67.49 M64.74 M—Nombre d'actions en circulation après dilution71.65 M71.46 M70.31 M67.66 M68.44 M65.77 M—EBITDA105.12 M103.06 M88.83 M44.36 M65.7 M233.83 M432.73 MEBIT60.24 M93.94 M79.72 M28.64 M17.49 M216.02 M341.87 MCoût des ventes142.56 M135.06 M137.03 M161.65 M165.91 M146.41 M611 MAutres coûts des ventes-1.64 M-1.38 M2.31 M1.93 M-667 K1.54 M5.12 MAmortissements (flux de trésorerie)44.88 M9.12 M9.12 M15.71 M48.21 M17.82 M90.86 M
Lantheus Holdings, Inc. - Common Stock
Lantheus, headquartered in Billerica, Massachusetts, is a company in the radiopharmaceuticals business. It has strategic partnerships with Bayer, Novartis, Regeneron as well as GE Healthcare and Siemens Healthineers.
Lantheus Holding, which became a NASDAQ company in 2015, is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden.
Brian Markison has served as the company's CEO since March 1, 2024, following the retirement of Mary Anne Heino, who had led Lantheus for the preceding decade.